Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biocryst Pharma Inc (NQ: BCRX )

8.800 USD +0.210 (+2.44%)
Official Closing Price Updated: 7:56 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biocryst Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), today announced they will be presenting at two upcoming healthcare-focused investor conferences. 
From GlobeNewswire News Releases
Great Point Partners, LLC Opposes The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc.
Great Point Partners, LLC ("GPP") today submitted a letter to the Board of Directors of BioCryst Pharmaceuticals, Inc. ("BCRX") expressing its opposition to BCRX's proposed merger with Idera... 
From PR Newswire
Global Pharmaceutical Over-the-counter Latest Advancements Boosting OTC Drugs Market Growth
From PR Newswire
SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of BioCryst Pharmaceuticals, Inc. - BCRX
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, is investigating the Board of... 
From PR Newswire
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Idera Pharmaceuticals, Inc. (IDRA) on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire is Investigating the Board of Directors of Idera (IDRA) on Behalf of Stockholders and Encourages Investors to Contact the Firm 
From Business Wire News Releases
BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), today announced that they have signed a definitive merger agreement to form a new enterprise focused on the... 
From GlobeNewswire News Releases
BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Progressiva
Novel approach using ALK2 inhibition 
From GlobeNewswire News Releases
BioCryst to Present at the 36th Annual J.P. Morgan Healthcare Conference
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the... 
From GlobeNewswire News Releases
Quotidian Technical Highlights on Selected Biotech Stocks -- Clovis Oncology, Exelixis, Celgene, and BioCryst Pharma
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on CLVS, EXEL, CELG, and BCRX which can be accessed for free by signing up to... 
From PR Newswire
Market Trends Toward New Normal in Ashland Global, BioCryst Pharmaceuticals, PICO, Chicago Rivet & Machine, Mercury General, and IQVIA Holdings — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ashland Global Holdings... 
From GlobeNewswire News Releases
Biotech Stock Performance Review -- BioCryst Pharma, Celgene, Exelixis, and Geron
From PR Newswire
BioCryst to Present at 29th Annual Piper Jaffray Healthcare Conference
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the... 
From GlobeNewswire News Releases
BioCryst Reports Third Quarter 2017 Financial Results
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the third quarter ended September 30, 2017. 
From GlobeNewswire News Releases
BioCryst to Present at the Jefferies 2017 London Healthcare Conference
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the... 
From GlobeNewswire News Releases
BioCryst Announces Late Breaker Presentation of BCX7353 Phase 2 APeX-1 Trial Results at the ACAAI’s 2017 Annual Scientific Meeting
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that results from its successful Phase 2 APeX-1 clinical trial in hereditary angioedema (HAE) will be presented at the American College of... 
From GlobeNewswire News Releases
BioCryst to Announce Third Quarter 2017 Financial Results on November 7
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its third quarter 2017 financial results will be reported on Tuesday, November 7, 2017. 
From GlobeNewswire News Releases
Breakfast Technical Briefing on Biotech Stocks -- BioCryst Pharma, Celgene, Juno Therapeutics, and Lexicon Pharma
From PR Newswire
BioCryst Announces RAPIVAB® (peramivir injection) and Galidesivir Presentations at IDWeek 2017™
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that interim results from a clinical trial of a single IV dose of RAPIVAB® (peramivir injection) for the treatment of pediatric influenza... 
From GlobeNewswire News Releases
Few Biotech Stocks Keep Momentum Going With Key Developments and FDA Approvals
MarketNewsUpdates.com News Commentary 
From PR Newswire
BioCryst’s RAPIVAB® (peramivir injection) Receives FDA Approval for a Pediatric Indication
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today that the U.S. Food... 
From GlobeNewswire News Releases
BioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced today the completion of an underwritten public offering of 17,864,078 shares of its common stock, including 2,330,097 shares sold pursuant to the... 
From GlobeNewswire News Releases
BioCryst Meeting with FDA to Design Phase III Trial for BCX7353 and PDUFA Review for RAPIVAB
From ACCESSWIRE
BioCryst Pharmaceuticals Prices Public Offering of Common Stock
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced today the pricing of an underwritten public offering of 15,533,981 shares of its common stock, offered at a price to the public of $5.15 per... 
From GlobeNewswire News Releases
BioCryst Pharmaceuticals Commences Public Offering of Common Stock
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today that it is offering... 
From GlobeNewswire News Releases
Technical Snapshots for These Biotech Stocks -- Alnylam Pharma, Alexion Pharma, Albany Molecular Research, and BioCryst Pharma
From PR Newswire
BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced final results from its Phase 2 APeX-1 clinical trial in hereditary angioedema (HAE). APeX-1 was a 3-part dose ranging trial designed to... 
From GlobeNewswire News Releases
BioCryst Announces Corporate Update Conference Call and Webcast
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company will host a conference call on Tuesday, September 5, 2017, at 9:00 a.m. Eastern Time to provide an update... 
From GlobeNewswire News Releases
BioCryst to Present at Three Upcoming Investor Conferences
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the... 
From GlobeNewswire News Releases
BioCryst Reports Second Quarter 2017 Financial Results
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the second quarter ended June 30, 2017. 
From GlobeNewswire News Releases
BioCryst Announces Initiation of ZENITH-1, a Clinical Trial to Evaluate BCX7353 as an Acute Treatment of Hereditary Angioedema Attacks
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the dosing of the first subject into ZENITH-1, a clinical trial studying up to three dosage strengths of a liquid formulation of BCX7353... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account